NCT01139177UnknownNot Applicable
SAMBA EU Femoropopliteal Trial
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- NovoStent Corporation
- Enrollment
- 39
- Locations
- 4
- Primary Endpoint
- The primary safety endpoint is defined as freedom from all cause death, unplanned index limb amputation, and target lesion revascularization.
Study Overview
Brief Summary
The primary objective of this study is to evaluate the safety and performance of the SAMBA Stent and Delivery System in the treatment of femoropopliteal lesions.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 21 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient must be ≥ 21 years of age with life expectancy > 1 year.
- •Symptomatic leg ischemia requiring treatment of the superficial femoral and/or popliteal artery (Rutherford category 2-4; claudication, rest pain).
- •Patient must be a suitable candidate for PTA and stenting.
- •Patient is willing and able to return to the site of the investigation at the specified study intervals and undergo follow-up requirements.
- •The patient or legal representative has provided written informed consent using a form that is reviewed and approved by the EC for the Clinical Site.
- •Pre-Intervention
- •Target lesion has ≥ 50% stenosis as demonstrated angiographically.
- •Lesion length ≤ 15 cm.
- •Reference vessel diameter of 5 to 6 mm.
- •Patient has at least 1 vessel run-off prior to treatment.
Exclusion Criteria
- •The subject is pregnant or will become pregnant during the study or has any other condition that would preclude having x-rays. (Pre-menopausal women must have a negative pregnancy test within 7 days of the procedure.)
- •Patients who have experienced a cardiovascular accident (CVA) or a myocardial infarction (MI) within 3 months prior to the procedure.
- •Subject has had or plans to have a surgical or interventional procedure within 30 days before or after the implantation procedure of the SAMBA Stent.
- •Existing hemorrhagic disease or coagulation problems or inability to take dual anti-platelet therapy.
- •Contrast allergy that cannot be corrected with medication (e.g. steroids, etc.).
- •Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment.
- •Patient is currently participating in another investigational drug or device study.
- •Pre-Intervention
- •Uncorrectable severe aorto-iliac occlusive disease or severe common femoral artery stenosis preventing access or limiting inflow (e.g., stenosis greater than 50%).
- •Uncorrectable occlusive disease limiting outflow (e.g., stenosis greater than 50%)
- •Patients with previous surgery in the target vessel or stent that will be closer than 2 cm to either edge of SAMBA Stent(s).
- •Lack of 1 cm of healthy vessel proximal to proximal target
- •Lack of popliteal reconstitution (at least 2 cm of normal distal popliteal).
- •Inability to cross the lesion with a guidewire.
- •More than 1 lesion in the same limb requiring treatment that will not be covered by continuous stenting.
- •Unsuccessful balloon pre-dilation (i.e., the residual stenosis is greater than 30%).
Outcomes
Primary Outcomes
The primary safety endpoint is defined as freedom from all cause death, unplanned index limb amputation, and target lesion revascularization.
Time Frame: through 30 days
The primary efficacy endpoint is defined as stent patency via Color Duplex Ultrasound (Peak Velocity Ratio ≤ 2.5).
Time Frame: 3 months
Secondary Outcomes
- Clinically-Driven Target Lesion Revascularization (i.e., with documented preintervention evidence of at least 50% diameter stenosis (quantitative angiographic ≥ 50% or PSVR > 2.5).(12 months)
- Change in Rutherford Classification compared to pre-implant.(12 months)
- Stent Patency via Color Duplex Ultrasound (Peak Systolic Velocity Ratio ≤ 2.5).(12 months)
- Stent Fractures.(12 months)
Investigators
Study Sites (4)
Loading locations...
Similar Trials
Completed
Not Applicable
SuperNOVA Clinical Stenting TrialAtherosclerosis of Native Arteries of the Extremities, UnspecifiedNCT01292928Boston Scientific Corporation299
Completed
Not Applicable
Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD Study)Paclitaxel Adverse ReactionSafety IssuesPeripheral Arterial DiseaseNCT04496544Beth Israel Deaconess Medical Center168,553
Completed
Not Applicable
Wingspan Stent System for Intracranial Artery StenosisIntracranial Artery StenosisStentEndovascular TherapyNCT06618222The First People's Hospital of Changzhou43
Unknown
Not Applicable
BioFreedom™ BA9™ UltraCardiovascular DeathRevascularizationMyocardial InfarctionNCT05331547The University of Hong Kong50
Completed
Not Applicable
Stenting of the Superficial Femoral and/or Proximal Popliteal Artery ProjectAtherosclerosis of Native Arteries of the ExtremitiesNCT01820637Boston Scientific Corporation57